Experts of the HARMONY Alliance will be presenting at the 48th EBMT Annual Meeting. Due to the current crisis in Ukrain, EBMT2022 will be organized as a virtual event., it will take place from 19-23 March 2022.
The EBMT is a highly valued HARMONY and HARMONY PLUS Partner.
Learning about Big Data innovations and new ‘tools’ to rapidly select the most promising treatment for blood cancer patients; that is what the Joint Session at EBMT2022 will offer to bone marrow transplant professionals.
Speakers and topics
What value can Big Data technology add in the daily practice of bone marrow transplant professionals: Anna Sureda, EBMT President and HARMONY Partner
Introducing the HARMONY Alliance [HARMONY and HARMONY PLUS]|: Jesús M Hernández, HARMONY IBSAL and HARMONY Coordinator
Doing research within the HARMONY Alliance in AML: results, projects ahead, and core outcome sets development: Lars Bullinger, Charité and Leader HARMONY Work Package Definitions of Outcomes
The HARMONY Machine Learning Researching Tool to predict the risk of relapse after 1st Remission in AML Patients treated without Allogeneic Haematopoietic Stem Cell Transplantation: Marta Sobas, Wroclaw Medical University, HARMONY Associated Member
The EBMT vision on potential opportunities for scientific collaboration between EBMT and HARMONY in AML: Fabio Ciceri, EBMT Scientific Council, IRCCS Ospedale San Raffaele
The HARMONY unique data anonymization concept, OMOP common data model for harmonizing and using data, and how HARMONY could help the EBMT to amplify its relevance and envision: Laura Tur Giménez, GMV and Leader HARMONY Work Package Data Access
The building of a new EBMT platform: Coping with the needs of widening and easing collaboration with other international cell therapy registries/organizations: Bas Middelkoop, EBMT Registry
The need for a public-private partnership incorporating all stakeholders involved in the management of hematologic malignancies for the benefit of the patients: Guillermo Sanz, Health Research Institute La Fe and HARMONY Co-Chair
Expectancies of the pharmaceutical industry in a successful EBMT-HARMONY collaboration: Frederico Calado, Novartis Oncology and HARMONY Project Leader
Closing message by HARMONY Patient Cluster: Tamas Bereczky, Leukanet, HARMONY Patient Cluster Partner and HARMONY Patient Cluster Lead and Solène Clavreul, Myeloma Patients Europe, HARMONY Patient Cluster Partner
#bigdataforbloodcancer: Accelerating Better and Faster Treatment for Patients with Hematologic Malignancies.
The HARMONY Alliance (HARMONY and HARMONY PLUS) is a public-private European Network of Excellence for Big Data in Hematology. Our mission is to unlock and spread valuable knowledge on hematologic malignancies (blood cancers) among a large number of stakeholders, with the goal to harness and mine Big Data to speed up the development of improved treatments for patients and more effective treatment strategies.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
